Vertex Pharmaceuticals is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases and cancer.
Type
Public
HQ
Boston, US
Founded
1989
Size (employees)
2,300 (est)+7%
Website
vrtx.com
Vertex Pharmaceuticals was founded in 1989 and is headquartered in Boston, US
Report incorrect company information

Key People/Management at Vertex Pharmaceuticals

Jeffrey Leiden

Jeffrey Leiden

Chairman, President and CEO
Stephanie Franklin

Stephanie Franklin

Senior Vice President and Chief Human Resources Officer
David Altshuler

David Altshuler

Executive Vice President, Global Research and Chief Scientific Officer
Stuart Arbuckle

Stuart Arbuckle

Executive Vice President and Chief Commercial Officer
Reshma Kewalramani

Reshma Kewalramani

Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer
Michael Parini

Michael Parini

Executive Vice President, Chief Legal and Administrative Officer
Show more

Vertex Pharmaceuticals Office Locations

Vertex Pharmaceuticals has an office in Boston
Boston, US (HQ)
50 Northern Ave
Show all (1)
Report incorrect company information

Vertex Pharmaceuticals Financials and Metrics

Vertex Pharmaceuticals Financials

Vertex Pharmaceuticals's revenue was reported to be $2.49 b in FY, 2017
USD

Revenue (FY, 2017)

2.5 b

Net income (FY, 2017)

91.6 m

EBIT (FY, 2017)

123.2 m

Market capitalization (23-Apr-2018)

40.2 b

Cash (31-Dec-2017)

1.7 b
Vertex Pharmaceuticals's current market capitalization is $40.2 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

1.2 b580.4 m1 b1.7 b2.5 b

Revenue growth, %

(52%)78%65%

R&D expense

1 b1.3 b

Operating expense total

1 b2.4 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

221.7 m118.5 m138.4 m179 m138.5 m166.1 m309.8 m398.1 m431.6 m413.8 m714.7 m544.1 m

R&D expense

228.6 m239 m224.8 m190.9 m215.6 m223.9 m246.3 m255.9 m271 m272.4 m273.6 m289.5 m

Operating expense total

355.8 m334.8 m319.3 m321.2 m310.5 m337.2 m379.8 m412.4 m428.3 m432.5 m443.9 m491.4 m

EBIT

(134.1 m)(216.4 m)(180.8 m)(142.2 m)(172 m)(171.2 m)(70 m)(14.3 m)3.4 m(18.7 m)270.8 m52.7 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

569.3 m625.3 m714.8 m1.2 b1.7 b

Accounts Receivable

85.5 m76 m177.6 m201.1 m281.3 m

Inventories

14.1 m30.8 m57.2 m77.6 m111.8 m

Current Assets

1.6 b1.5 b1.4 b1.8 b2.6 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

583.2 m424 m420.6 m718.6 m664.9 m870.5 m756.3 m604.2 m605.9 m719.7 m1 b1.2 b

Accounts Receivable

120.3 m59.9 m81.8 m114.3 m80.3 m94.5 m165.3 m181.9 m189.4 m182.2 m208 m247.9 m

Inventories

13.5 m11.3 m12 m16.8 m34.1 m42.1 m49.2 m63.2 m66.6 m71.8 m82 m92.3 m

Current Assets

1.6 b1.4 b1.3 b1.7 b1.4 b1.3 b1.4 b1.4 b1.5 b1.5 b1.9 b2.2 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(687.6 m)(742.7 m)(588.2 m)(84 m)91.6 m

Depreciation and Amortization

48.4 m63.3 m62.3 m61.4 m61.4 m

Inventories

7.1 m(16 m)(23 m)(16.5 m)(45 m)

Accounts Payable

(49.2 m)25 m(1.7 m)(11.7 m)8.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(128.7 m)(232.5 m)(159.4 m)(198.7 m)(391.8 m)(561.9 m)(36.1 m)(72.3 m)(111.8 m)249.5 m(72.3 m)

Depreciation and Amortization

16.4 m31.4 m45.9 m14.9 m

Inventories

42.1 m49.2 m(4.8 m)(7.8 m)(11.5 m)(3.7 m)

Accounts Payable

72.7 m78.9 m(343 k)(23.8 m)(21.5 m)717 k
USDY, 2017

Revenue/Employee

1.1 m

Financial Leverage

1.7 x
Show all financial metrics
Report incorrect company information